logo
  • Home
  • About
  • Activist Campaigns
  • Newsroom
  • Our Impact
  • Contact
  • Private Capital

broadcast

Kohl’s putting in a poison pill is unprecedented after only two weeks, says Macellum CEO

by karl@kuraldesign.com

Recent Posts

  • Kohl’s snub of big sale-leaseback sets up new clash with hedge funds
  • Kohl’s board needs more change to be the darling of retail again, says Macellum CEO Jonathan Duskin
  • Macellum Issues Letter to Fellow Shareholders Regarding its Desire to Collaborate with the Kohl’s Board of Directors on an Immediate and Targeted Refresh
  • Activist Investor Urges Kohl’s to Replace Board Members
  • ISS Recommends SpartanNash Shareholders Vote for Boardroom Change on Macellum and Ancora’s BLUE Proxy Card

Recent Comments

No comments to show.

Archives

  • November 2022
  • October 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • October 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • October 2019
  • May 2019
  • April 2019
  • March 2019
  • September 2017
  • May 2017
  • March 2016
  • May 2015
  • March 2015
  • November 2014

Categories

  • Commentary
  • News
  • Video

60 Broad Street
Suite 3825
New York, NY 10004

Quick Links

  • Home
  • About
  • Activist Campaigns
  • Newsroom
  • Our Impact
  • Contact

Macellum Advisors, LP, the investment adviser affiliate of Macellum Capital Management, is a Registered Investment Advisor regulated by the U.S. Securities and Exchange Commission (“SEC”) subject to the Rules and Regulations of the Investment Advisers Act of 1940. Registration with the SEC does not imply a certain level of skill or training.

© Macellum Capital Management. All rights reserved. Privacy Policy.

Information provided on this website does not constitute an offer or solicitation to subscribe for or purchase any securities in any jurisdiction. Any such offer or solicitation will only be made pursuant to a confidential offering memorandum, which will contain material information not contained on this website, including material information regarding investment risks and conflicts of interest. Any investment decision should be made solely upon, and after reviewing, the information contained in the applicable offering memorandum. Past performance is not indicative of future results. Expected or targeted returns are forward-looking statements that are subject to uncertainty as described further in the applicable offering memorandum and should not be regarded as a representation, warranty or prediction of any particular performance.